Company intelligence / Profile preview

Abnoba

Niefern-Öschelbronn, Baden-Württemberg, Germany

Ownership: Private
Development stage: Other

Overview

abnobaVISCUM, the company's line of mistletoe-based injectable biologics, is widely used in integrative oncology in the EU and is currently in a phase 3 trial (TIM study) for prevention of recurrence of superficial bladder carcinoma; real-world evidence and studies suggest it improves survival in combination with immune checkpoint blockade for advanced non-small cell lung cancer[7][8][10][1].

Therapeutic areas: Oncology
Modalities: BiologicHerbal medicinal product
Industry: Biotech

Beyond the preview

Go deeper on Abnoba.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Abnoba.

Explore the full profile